MARKET

OTIC

OTIC

Otonomy
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.510
-0.050
-1.95%
Opening 14:42 11/22 EST
OPEN
2.560
PREV CLOSE
2.560
HIGH
2.600
LOW
2.510
VOLUME
32.64K
TURNOVER
--
52 WEEK HIGH
3.155
52 WEEK LOW
1.500
MARKET CAP
77.18M
P/E (TTM)
-1.6531
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of OTIC and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

OTIC News

  • Edited Transcript of OTIC earnings conference call or presentation 5-Nov-19 9:30pm GMT
  • Thomson Reuters StreetEvents.1d ago
  • Otonomy EPS beats by $0.12, misses on revenue
  • seekingalpha.11/06 02:35
  • Otonomy (OTIC) Reports Q3 Loss, Lags Revenue Estimates
  • Zacks.11/05 23:55
  • Otonomy Q3 EPS $(0.33) Beats $(0.45) Estimate, Sales $125K Miss $210K Estimate
  • Benzinga.11/05 21:30

More

Industry

Biotechnology & Medical Research
+1.64%
Pharmaceuticals & Medical Research
+0.72%

Hot Stocks

Name
Price
%Change

About OTIC

Otonomy, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company's product candidates include OTIPRIO, OTO-104 and OTO-311. OTIPRIO is a single-dose, physician-administered antibacterial, which is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery and is available for commercial purchase. OTO-104 is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Meniere's disease and other inner ear conditions. OTO-311 is a sustained-exposure formulation of the N-Methyl-D-Aspartate (NMDA) receptor antagonist gacyclidine in development for the treatment of tinnitus. It also has various other product candidates, which target sensorinerual hearing loss, including age-related hearing loss, also known as presbycusis.
More

Webull offers Otonomy Inc (OTIC) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.